Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug to see if it's safe and effective in treating advanced solid tumors. Participants will visit the site regularly and receive treatments, with tests to check safety and cancer progression.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had lung inflammation that needed steroids or have it now.You are allergic to any of the ingredients in the KVA12123 drug.I have brain metastases or spinal cord issues that haven't been treated.I finished curative radiation 2 weeks ago or palliative radiation for non-brain issues 1 week ago.I haven't taken steroids or immunosuppressants in the last 14 days.I have had a transplant or adoptive T-cell therapy in the past.I have previously been treated with VISTA-targeted therapy.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I haven't had cancer treatment or been in a cancer study in the last 4 weeks.I need daily supplemental oxygen.I am HIV-positive and have had Kaposi sarcoma or Multicentric Castleman Disease.You are pregnant, as confirmed by a urine test within 72 hours of starting the study drug.I am 18 years old or older.My organs are functioning well enough for treatment.I do not have another cancer needing treatment besides the one being studied.I have not had a live vaccine in the last 30 days.I have fully recovered from any major surgery I've had.I have agreed to provide samples of my previous biopsy or surgery for the study.I am a post-menopausal woman or I am surgically sterile.I have another cancer that is getting worse or was treated in the last 3 years.I have been diagnosed with active or latent tuberculosis.I am fully active or can carry out light work.My thyroid function is normal or I have stable hypothyroidism with treatment.I stopped a cancer treatment due to a severe side effect.I have an autoimmune disease treated in the last year.I had radiation therapy less than 2 weeks ago or have had lung inflammation from radiation.I've had lung radiation therapy of more than 30 Gy in the last 6 months.I have serious or uncontrolled heart problems.I have chronic hepatitis B or C.I am currently being treated for an infection.Side effects from my previous cancer treatments have not fully improved.I have not had a blood or platelet transfusion in the last 2 weeks.I stopped taking targeted therapy or similar drugs 2 weeks ago.My advanced cancer did not respond to standard treatments and cannot be cured.You are expected to live for at least 16 weeks.You have a disease that can be measured using a specific method called iRECIST.I have had cancer treatment before, but it's been over 4 weeks since my last dose.I am HIV positive, on ART, and my HIV is well-controlled.I had hepatitis B but no longer need treatment as my tests are clear.I had hepatitis C but it's now undetectable and I've completed treatment.
- Group 1: KVA12123 Plus Pembrolizumab Dose Expansion
- Group 2: KVA12123 Monotherapy Dose Expansion
- Group 3: KVA12123 Monotherapy Dose Escalation
- Group 4: KVA12123 Plus Pembrolizumab Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities to partake in this study?
"Affirmative, the study is currently seeking enrollees. The trial was initially posted on March 3rd 2023 and has since been updated on the same date. It requires 314 individuals to be recruited from 2 different medical facilities."
What is the aggregate amount of participants involved in this experiment?
"Affirmative. The clinical trial's webpage on clinicaltrials.gov attests to its active recruitment of participants, which began on March 3rd 2023 and was last updated the same day. It is currently looking for 314 individuals from 2 separate sites."
What is the fundamental purpose of this trial?
"This clinical experiment will be assessing the RP2D or MTD of a drug over one year as its primary outcome. Additionally, secondary goals are to measure partial response in patients, peak serum concentration time (tmax), and change from baseline anti-KVA12123 antibodies in serum concentrations."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger